Heart

These ingredients are often used in alternative medicine to support heart.

• acetyl-L-carnitineScientific

  Acetyl-L-Carnitine (ALC) has documented clinical evidence supporting cardiovascular benefit, particularly in heart ischemia and congestive heart failure. Its primary mechanism involves facilitating mitochondrial fatty acid oxidation, the heart's dominant energy pathway. Multiple clinical trials and meta-analyses of carnitine analogs—including ALC—show improvements in cardiac function markers, exercise tolerance, and mortality outcomes in cardiac patients.

• adzuki beanScientific

  Adzuki bean polyphenol extract improved HDL-C in a human RCT, with HDL maintenance persisting across 8 weeks. Animal studies show adzuki bean reduces aortic lesion formation and blood pressure in hypertensive models. The bean's fiber, potassium, and polyphenol content all contribute to cardiac protection mechanisms.

• ALA (alpha-linolenic acid)Scientific

  Alpha-Linolenic Acid (ALA) is a plant-derived essential omega-3 fatty acid with documented associations with reduced cardiovascular disease (CVD) risk in both observational and clinical research. Meta-analyses of observational studies link higher ALA intake to approximately 10–20% lower risk of total CVD and fatal coronary heart disease. RCTs show ALA reduces triglycerides, systolic blood pressure, and inflammatory markers, though evidence for hard clinical endpoints is less definitive than for long-chain marine omega-3s (EPA/DHA). The overall evidence base is promising but not yet considered robust for specific clinical recommendations.

• ALA (alpha-lipoic acid)Scientific

  Alpha-Lipoic Acid (ALA) has multiple lines of human clinical evidence supporting cardiovascular benefit, including improved endothelial function, modest blood pressure reduction, and favorable cardiometabolic risk factor changes. A 2025–2026 multicenter RCT in ischemic heart failure patients found ALA (600 mg/day) significantly improved left ventricular ejection fraction and exercise capacity versus placebo over 24 months, though no significant difference in the primary composite outcome (hospitalization/mortality) was detected. Systematic reviews and meta-analyses of RCTs further support ALA's roles in improving endothelial function and reducing blood pressure, though effect sizes are modest and evidence is strongest in high-risk populations such as those with diabetes or metabolic syndrome.

• algal oilScientific

  Algal oil DHA reduces key cardiovascular risk factors including triglycerides and blood pressure while improving lipoprotein profiles. Marine omega-3 meta-analysis data (n=127,477 across 13 RCTs) show significant reductions in myocardial infarction and cardiovascular death with omega-3 supplementation, with algal oil confirmed bioequivalent to fish oil for DHA delivery.

• almondScientific

  Almonds have direct cardiological evidence: RCTs show reduced LDL-C, improved endothelial function, reduced lipoprotein(a) and oxidized LDL (atherosclerosis mediators), modest diastolic blood pressure lowering, and improved cardiac autonomic regulation (heart rate variability). The FDA qualified health claim for nuts and coronary artery disease applies to almonds.

• alpha D-ribofuranoseScientific

  D-ribose directly targets the energy-depleted failing or ischemic heart, with clinical trials documenting improvements in diastolic function, myocardial ATP production, ejection fraction in HFpEF, and exercise tolerance in CHF and CAD. It is the most extensively studied target organ for D-ribose supplementation.

• amaranthScientific

  Amaranth oil has been directly tested in a randomized placebo-controlled clinical trial of patients with coronary heart disease and hypertension. Squalene, polyunsaturated fatty acids, and bioactive peptides in amaranth reduce cardiac risk factors including LDL cholesterol, blood pressure, and oxidative stress. Potassium in amaranth leaves supports cardiac rate and cellular fluid balance.

• anchoviesScientific

  Anchovies provide EPA, DHA, selenium, niacin, and potassium — nutrients with converging direct cardioprotective effects. Multiple meta-analyses of RCTs confirm omega-3 fatty acids reduce cardiovascular mortality, arrhythmia risk, and non-fatal cardiac events. Selenium reduces oxidative stress in cardiomyocytes, while niacin lowers cardiotoxic triglycerides and LDL.

• anthocyaninsScientific

  Substantial clinical and epidemiological evidence supports a cardioprotective role for anthocyanins. Multiple meta-analyses of RCTs and prospective cohort studies show associations with reduced coronary heart disease risk, improved LDL cholesterol, and lower CVD mortality. Mechanistically, anthocyanins act via anti-inflammatory, antioxidant, and endothelial-function pathways, though results are not uniformly positive across all cardiovascular endpoints or populations.

• appleScientific

  Apple polyphenols directly benefit cardiac function through cholesterol lowering, blood pressure reduction, prevention of atherosclerotic plaque formation via LDL oxidation inhibition, and anti-inflammatory effects relevant to myocardial protection. Multiple RCTs and cohort studies support these cardioprotective effects.

• apple cider vinegarScientific

  ACV addresses heart-relevant risk parameters (glucose, cholesterol, triglycerides, blood pressure) confirmed across meta-analyses of RCTs. There are no direct cardiac structural or functional endpoint studies. The relationship is through cardiometabolic risk factor modulation rather than direct cardiac tissue effects.

• apricotScientific

  Documented pharmacological reviews of Prunus armeniaca list cardioprotective activity as a primary finding. Apricot melanoidins protect human cardiac endothelial cells from oxidative death in cell-based studies. Human clinical trials on bitter apricot seeds demonstrate favorable improvements in atherogenic lipid fractions. Multiple bioactive compounds in apricot fruit (potassium, fiber, polyphenols, carotenoids) collectively support cardiac function.

• arjunaScientific

  Terminalia arjuna (arjuna) has documented clinical evidence supporting its use for heart-related conditions, including chronic stable angina, congestive heart failure, and coronary artery disease. Multiple human trials — including double-blind, placebo-controlled, crossover designs — have reported reductions in angina frequency, improved exercise tolerance, and improved left ventricular ejection fraction. Evidence quality is promising but limited by small sample sizes and methodological variability; large multicentre RCTs are still lacking.

• artichokeScientific

  Artichoke leaf extract directly influences cardiovascular parameters through lipid-lowering, antioxidant, and vasodilatory mechanisms. Multiple RCTs confirm reduced total cholesterol, LDL, and triglycerides, as well as increased HDL. In vitro evidence shows ALE inhibits iNOS in coronary artery smooth muscle cells, and chlorogenic acids support eNOS-mediated vasodilation.

• ashitabaScientific

  DMC from ashitaba protected mice from prolonged myocardial ischaemia in a Nature Communications study via autophagy. Ashitaba also suppresses PAI-1 production in heart tissue of obese mice. Chalcone 4-HD had antihypertensive and lipid-lowering effects in hypertensive rat cardiac models.

• ashwagandhaScientific

  Animal studies demonstrate direct cardioprotective effects of ashwagandha against ischemia-reperfusion injury and doxorubicin-induced cardiotoxicity, with antioxidant enzyme preservation exceeding vitamin E. Human clinical data shows improvements in cardiac risk factors including blood pressure, lipid profiles, and inflammatory markers relevant to heart health.

• astaxanthinScientific

  Astaxanthin, a xanthophyll carotenoid, has human clinical evidence supporting cardiovascular benefits, primarily through antioxidant and anti-inflammatory mechanisms. Small clinical studies show reductions in oxidative stress biomarkers, improvements in LV ejection fraction in heart failure patients, and modest favorable effects on lipid profiles and blood pressure. Evidence is promising but limited by small sample sizes and short study durations; large-scale cardiovascular outcome trials are lacking.

• astragalusScientific

  AS-IV and astragalus root preparations are directly cardioprotective, reducing myocardial injury markers, improving ejection fraction, and protecting cardiomyocytes from apoptosis and fibrosis. Clinical trials document benefit in heart failure and viral myocarditis. Traditional Chinese medicine has classified astragalus as a heart tonic for millennia.

• ATP (adenosine triphosphate)Scientific

  ATP is the primary energy currency of cardiomyocytes and acts via purinergic receptors to regulate cardiac function, including heart rate and contractility. Clinical evidence includes a human RCT showing oral ATP disodium (400 mg) accelerated heart rate variability recovery and reduced systolic blood pressure in hypertensive women after aerobic exercise. Cardiac and vascular function have also been reported to improve in animal models after 30 days of oral ATP supplementation.

• bananaScientific

  Banana's potassium, dietary fiber, and polyphenols support direct and indirect cardiac benefit. Potassium is essential for cardiac action potential and rhythm; hypokalemia is a recognized cause of arrhythmia, and dietary potassium from bananas helps maintain normal serum potassium. SSaSS cohort data linked increased potassium intake to significantly fewer major cardiovascular events.

• barberryScientific

  The heart is a direct target for barberry's alkaloids: berberine has antiarrhythmic, cardioprotective, and anti-heart-failure properties, while berbamine protects against ischemia-reperfusion injury. These effects are pharmacologically established and supported by experimental and some clinical data.

• barleyScientific

  Barley's β-glucan lowers LDL cholesterol and non-HDL cholesterol, reduces triglycerides, and has been linked to lower blood pressure — all major modifiable cardiovascular risk factors directly affecting cardiac health. FDA and EFSA health claims specifically recognize barley β-glucan for reducing coronary heart disease risk.

• barrenwortScientific

  Icariin demonstrates cardioprotective activity in isoproterenol-induced heart failure rat models, reversing hemodynamic decline, reducing oxidative stress, suppressing NF-κB/caspase-3, and elevating cGMP and Nrf2. ICA also promotes differentiation of stem cells into cardiomyocytes. Epimedium prenylflavonoids have demonstrated cardiovascular benefits including improved endothelial function in human subjects.

• bee pollenScientific

  Bee pollen polyphenols reduce multiple cardiac risk factors including ox-LDL, ACE activity, angiotensin II, and dyslipidemia in animal models. Fermented bee pollen postbiotics modulate the cardiovascular-relevant gut microbiota. The German Federal Board of Health has recognized bee pollen as a medicine including for cardiac-adjacent indications.

• beetScientific

  Beetroot nitrate reduces cardiac workload by lowering systemic vascular resistance and blood pressure, thereby reducing afterload on the heart. RCT evidence confirms reduced heart rate and improved cardiac efficiency during submaximal exercise in several populations.

• belleric myrobalanScientific

  Animal studies demonstrate T. bellirica extract reduces CK-MB enzyme (a specific cardiac injury marker), reduces cardiac tissue MDA (oxidative stress), and increases cardiac antioxidant enzymes against drug-induced cardiotoxicity. Traditional Ayurvedic use includes prevention of heart tissue death. In vitro evidence shows anti-atherogenic potential via LDL oxidation inhibition and macrophage inflammation suppression.

• berberineScientific

  Berberine has substantial human clinical evidence supporting cardiovascular benefit, particularly for dyslipidemia, heart failure, and arrhythmia. Multiple RCTs and meta-analyses demonstrate meaningful reductions in LDL-C, total cholesterol, and triglycerides. Clinical studies also show improved cardiac output and reduced ventricular arrhythmias in heart failure patients. Mechanistically, berberine exhibits positive inotropic, antiarrhythmic, and vasodilator properties via ion-channel modulation.

• beta-glucanScientific

  Beta-glucan, a soluble fiber from oats and barley, has robust clinical evidence supporting its ability to lower LDL and total cholesterol, key cardiovascular risk factors. Both the FDA (1997) and EFSA (2010–2011) have authorized health claims linking at least 3 g/day of beta-glucan to reduced risk of coronary heart disease. Multiple meta-analyses of randomized controlled trials confirm significant, consistent reductions in LDL-C and total cholesterol at this dose.

• beta-sitosterolScientific

  Beta-sitosterol lowers LDL cholesterol by competitively inhibiting intestinal cholesterol absorption, an effect recognized by the U.S. FDA, which permits a qualified health claim that diets including plant sterol esters may reduce coronary heart disease risk. Multiple clinical studies document LDL reductions with daily intakes of 2 g or more of phytosterols. Direct evidence that beta-sitosterol supplementation reduces cardiovascular events long-term is not yet established.

• betaineScientific

  Betaine's cardiac relevance is documented through homocysteine reduction — a risk factor for coronary artery disease — and prospective cohort data showing reduced cardiovascular mortality with higher dietary betaine in CAD patients. Betaine is used in homocystinuria to prevent vascular complications. Countervailing evidence shows betaine raises LDL cholesterol, potentially offsetting some benefit.

• blueberryScientific

  RCT and epidemiological evidence links blueberry/anthocyanin intake to reduced coronary heart disease risk and improved cardiac risk factors including lipids, endothelial function, and blood pressure. Anthocyanins modulate multiple cardioprotective pathways.

• bovine heartScientific

  Bovine heart is the single richest food source of CoQ10, the compound most concentrated in and essential to cardiac tissue. CoQ10 levels in the heart decline with age and with heart failure severity. Multiple RCTs and the Q-SYMBIO trial demonstrate CoQ10 supplementation improves heart function, ejection fraction, and reduces cardiovascular events. Traditional use of consuming animal heart for heart health is independently documented.

• brussel sproutsScientific

  Brussels sprouts contain glucosinolates, potassium, folate, omega-3 fatty acids, soluble fiber, and vitamin C — a combination with established roles in reducing LDL cholesterol, supporting blood pressure regulation, lowering homocysteine, and reducing vascular inflammation. Cleveland Clinic specifically identifies Brussels sprouts as an excellent addition to a heart-healthy diet.

• cabbageScientific

  Cabbage extract protected H9c2 cardiomyoblasts from oxidative stress-induced cell death and mitochondrial dysfunction in vitro. Cruciferous vegetables including cabbage are associated with lower CVD risk in prospective cohort meta-analyses, and the VESSEL RCT found significant blood pressure and triglyceride reductions.

• caffeineScientific

  Caffeine directly and indirectly affects cardiac function through adenosine receptor blockade, catecholamine release, and intracellular calcium modulation. It acutely increases heart rate in non-habitual users and elevates blood pressure, and modifies myocardial blood flow response to exercise. At very high doses it can produce tachyarrhythmias.

• calamari oilScientific

  DHA and EPA from calamari oil support cardiac function through triglyceride lowering, heart rate reduction, antiarrhythmic effects, and improvements in myocardial efficiency. These effects are supported by multiple large RCTs and meta-analyses. The FDA has issued a qualified health claim for EPA and DHA in coronary heart disease risk reduction.

• campesterolScientific

  Campesterol plasma levels have been directly investigated as a predictor of cardiac events in the KEEP cohort study, with higher levels associated with significantly fewer cardiovascular events. Phytosterol supplementation including campesterol also reduces LDL-C, the principal modifiable lipid risk factor for coronary heart disease.

• capsaicinoidsScientific

  TRPV1 receptors are expressed in cardiac tissue and play roles in cardioprotection, particularly in ischemia-reperfusion contexts. Capsaicin has been shown to preserve cardiac function and reduce ischemic injury in experimental models. Population data associate habitual capsaicin consumption with reduced cardiovascular mortality.

• cardamomScientific

  Cardamom has documented effects on cardiac risk factors through multiple RCTs: reducing blood pressure, triglycerides, total cholesterol, and key inflammatory markers. It is described as having 'cardioprotective' properties in peer-reviewed reviews based on the totality of clinical and mechanistic evidence. Antithrombotic and antioxidant properties further support cardiac protection.

• cassia barkScientific

  Cassia bark has documented effects on cardiac risk factors (lipids, glucose, CRP) in human clinical trials. Preclinical literature demonstrates cardiac ischemia and hypertrophy protective effects. In TCM, cassia bark is classified as a heart-channel herb.

• catalaseScientific

  Catalase protects the heart from oxidative injury, particularly in diabetic cardiomyopathy and age-related cardiac decline. Mitochondria-targeted catalase overexpression protects mice from cardiac aging phenotypes and extends lifespan. Catalase overexpression inhibits NF-κB-mediated autophagy and apoptosis in diabetic cardiac tissue.

• catechinsScientific

  Catechins — polyphenolic compounds abundant in green tea, cocoa, and certain fruits — have substantial human and clinical evidence supporting cardiovascular benefit. Multiple RCTs and meta-analyses demonstrate reductions in blood pressure, LDL cholesterol, and platelet aggregation, as well as improvements in endothelial (flow-mediated) vasodilation. Mechanistically, catechins act via antioxidant, anti-inflammatory, lipid-lowering, and nitric-oxide-enhancing pathways. Evidence strength is moderate; translating statistically significant findings into confirmed long-term clinical outcomes remains an open question.

• cauliflowerScientific

  Sulforaphane protects cardiomyocytes from oxidative stress via Nrf2, and preclinical studies show prevention of hypertension and preservation of cardiac function over several months. Fiber and potassium from cauliflower support healthy blood pressure and lipid profiles relevant to cardiac function.

• cayenne pepperScientific

  Capsaicin has direct cardioprotective actions including anti-ischaemic and antiarrhythmic effects documented in research, plus epidemiological evidence linking regular chili pepper consumption to lower cardiac mortality. TRPV1 is expressed in cardiac tissue, and its activation by capsaicin modulates cardiac function.

• cherryScientific

  Tart cherry juice has been shown in RCTs to reduce systolic blood pressure and LDL cholesterol in older adults, and to lower CRP and oxidative stress markers relevant to cardiac health. Pre-clinical evidence also shows cardioprotective effects against ischemia-reperfusion injury, though human cardiac endpoint trials are absent.

• chia seedScientific

  Chia seeds directly benefit cardiac function by reducing multiple heart disease risk factors in RCTs: SBP, LDL-C, triglycerides, and inflammation. ALA omega-3s are associated with reduced cardiovascular event risk. Animal studies confirm chia reduces cardiac oxidative stress and high-fat-diet-induced cardiac histopathological changes.

• chinese salvia rootScientific

  The heart is Danshen's primary organ target in both TCM and modern pharmacology. It is classified as entering the 'heart meridian,' and its cardiomyocyte-protective, anti-ischemic, anti-fibrotic, and anti-arrhythmic actions are supported by multiple clinical trials and pharmacological reviews.

• chokeberryScientific

  Chokeberry extract added to statin therapy enhanced cardiovascular risk marker reduction in post-myocardial infarction patients in a clinical study. Multiple RCTs show reductions in blood pressure and cholesterol, key cardiac risk factors. Animal studies confirm cardioprotective and anti-atherogenic effects including in aging models.

• cholineScientific

  The relationship between choline and the heart is well-documented but paradoxical. Dietary choline may offer certain cardioprotective effects (e.g., reducing homocysteine, supporting cardiac muscle function via acetylcholine/M3 receptor pathways), yet elevated plasma choline and its gut-microbiota-derived metabolite TMAO are consistently associated with increased risk of cardiovascular events including heart attack, stroke, atrial fibrillation, and heart failure. Large observational cohort studies report no significant association between dietary choline intake and coronary heart disease risk, while plasma choline levels show positive associations with incident CVD. The overall evidence base is substantial but contradictory, and the net cardiovascular effect of choline depends heavily on dose, form, gut microbiome composition, and baseline risk.

• citrus sinensisScientific

  C. sinensis hesperidin improves cardiac-relevant biomarkers including blood pressure, lipid levels, endothelial function, and vascular inflammatory markers across multiple RCTs. A meta-analysis of 12 human trials confirmed broad cardiovascular risk factor improvement. Hesperidin also demonstrates antithrombotic effects in preclinical models.

• cocoaScientific

  Cocoa flavanols directly improve cardiac function parameters. A 2025 RCT demonstrated cocoa flavanol intake reversed early diastolic dysfunction by reducing left atrial volume by 12.6% and LV end-diastolic volume by ~4.4% in healthy older adults. The COSMOS trial found a 27% reduction in CVD mortality with 500 mg/day flavanols.

• coconutScientific

  Coconut oil's effects on the heart are primarily mediated through its impact on blood lipids. It raises both LDL-C (atherogenic) and HDL-C; current evidence from major meta-analyses supports a net unfavorable cardiovascular risk profile versus unsaturated fats, though VCO may modestly reduce triglycerides.

• cod liver oilScientific

  Cod liver oil EPA and DHA reduce cardiac risk factors including triglycerides, platelet aggregation, and systemic inflammation. EPA has antiarrhythmic properties by modulating cardiac ion channels. CLO is associated with reduced myocardial infarction risk in interventional studies.

• coenzyme AScientific

  Coenzyme A (CoA) and its derivatives — particularly acetyl-CoA, acyl-CoA, and malonyl-CoA — are central to cardiac energy metabolism, supplying the heart with its primary fuel via fatty acid β-oxidation and the TCA cycle. The heart, one of the highest-energy-demand organs in the body, relies on CoA-dependent pathways to sustain continuous ATP production. Disruptions in CoA metabolism are mechanistically linked to heart failure, ischemic heart disease, obesity-related cardiomyopathy, and cardiac hypertrophy.

• coleus forskohliiScientific

  Forskolin directly activates myocardial adenylate cyclase in human heart tissue, producing potent positive inotropic effects—greater than isoproterenol in failing hearts. Two clinical trials with IV forskolin in heart failure patients showed positive effects. Ayurvedic tradition uses Coleus for heart disease.

• CoQ10 (coenzyme Q10)Scientific

  CoQ10 has substantial clinical evidence supporting its role in heart health, particularly in heart failure (HF). It functions as an essential electron carrier in mitochondrial ATP production and as a lipid-soluble antioxidant, addressing the bioenergetic deficits characteristic of failing cardiac tissue. The landmark Q-SYMBIO randomized double-blind trial (n=420) found that CoQ10 at 300 mg/day significantly reduced major adverse cardiovascular events and all-cause mortality compared to placebo over two years. Multiple meta-analyses of RCTs also report modest but significant improvements in left ventricular ejection fraction in HF patients.

• cordycepsScientific

  Cordyceps exerts direct cardiac effects including anti-arrhythmic activity documented in a meta-analysis of 19 RCTs (1,805 patients), protective effects against cardiac hypertrophy via AMPKα activation, and increased cardiac output in a heart failure study. Adenosine in Cordyceps stabilizes cardiomyocyte electrical activity. Ischemic myocardial reperfusion injury protection has been demonstrated in preclinical models.

• creatineScientific

  The heart depends critically on the phosphocreatine/creatine kinase energy buffering system, consuming more ATP per gram than any other organ. Cardiac creatine depletion is established as a hallmark of heart failure, correlates with ejection fraction, and predicts mortality. Early clinical trials support creatine's role in improving skeletal muscle performance and vascular function in cardiac patients.

• creatine monohydrateScientific

  Creatine is an essential component of cardiac energy metabolism, with the phosphocreatine-creatine kinase system serving as the primary ATP buffer in cardiomyocytes. Supplementation increases cardiac creatine content, and research identifies potential roles in heart failure, ischemia protection, and cardioprotection during anthracycline chemotherapy.

• curcuminScientific

  Multiple randomized controlled trials and systematic reviews demonstrate that curcumin supports cardiovascular health by improving endothelial function, modestly reducing blood pressure, and favorably altering lipid profiles. Its primary mechanisms involve inhibition of NF-κB–driven inflammation, reduction of oxidative stress, and enhancement of nitric oxide bioavailability. Clinical evidence is promising but limited by curcumin's poor oral bioavailability, and large-scale outcome trials are still lacking.

• D-riboseScientific

  D-ribose is the most clinically investigated supplement for cardiac energy metabolism, with multiple published human trials showing improved diastolic function, increased ischemic threshold, and better quality of life in patients with CHF and coronary artery disease. The mechanism is direct acceleration of myocardial ATP biosynthesis via PRPP.

• daidzinScientific

  Preclinical studies demonstrate cardioprotective effects of daidzin/daidzein including reduction of myocardial infarction markers, antiarrhythmic properties, increased cardiac nitric oxide, and anti-inflammatory protection. Clinical evidence remains limited to modest lipid-lowering effects.

• DHA (docosahexaenoic acid)Scientific

  DHA (docosahexaenoic acid), a marine-derived omega-3 fatty acid, has robust clinical and epidemiological evidence supporting its role in cardiovascular health. It reliably reduces fasting and postprandial triglycerides, modestly raises HDL-cholesterol, lowers resting heart rate and blood pressure, and improves endothelial function. Meta-analyses of randomized controlled trials link higher EPA+DHA intake to reduced cardiovascular mortality and non-fatal myocardial infarction, though high-dose supplementation carries an increased risk of atrial fibrillation.

• docosahexaenoic acidScientific

  DHA directly benefits cardiac structure and function, reducing heart rate, blood pressure, triglycerides, platelet thrombogenicity, and oxidative stress-mediated myocardial damage. DHA improves left ventricular ejection fraction in heart failure and reduces sudden cardiac death risk. High-dose supplementation may increase atrial fibrillation risk.

• dong quaiScientific

  Pharmacological studies demonstrate A. sinensis protects cardiac myocytes from apoptosis via ferulic acid-mediated autophagy enhancement, reduces myocardial fibrosis via polysaccharides, and exhibits antiarrhythmic properties via sodium ferulic acid and quinidine-like actions. TCM classifies Dong Quai as a cardiac tonic acting on the heart meridian.

• DPA (docosapentaenoic acid)Scientific

  Higher plasma DPA concentrations are associated with lower risk of fatal coronary heart disease and myocardial infarction across multiple large prospective studies. DPA reduces cardiovascular inflammation by lowering inflammatory gene expression in arterial walls and generating SPMs, while its potent antiplatelet activity reduces acute coronary thrombotic risk.

• EGCG (epigallocatechin gallate)Scientific

  EGCG (Epigallocatechin Gallate), the principal bioactive catechin in green tea, has a well-documented scientific relationship with cardiovascular/heart health. Clinical studies confirm it acutely improves endothelial function and brachial artery flow-mediated dilation in coronary artery disease patients, and meta-analyses of randomized controlled trials show modest but significant reductions in systolic and diastolic blood pressure. Mechanistically, EGCG modulates nitric oxide production, reduces oxidative stress and inflammation, attenuates adverse cardiac remodeling, and inhibits atherosclerotic pathways. While preclinical evidence is robust, further large-scale RCTs are needed to fully establish optimal dosing and long-term clinical outcomes.

• eicosapentaenoic acidScientific

  EPA directly benefits the heart via antiarrhythmic effects (ion channel modulation), anti-inflammatory plaque stabilization, triglyceride lowering (reducing cardiac lipotoxicity), and reduced thrombotic risk. The REDUCE-IT trial established that high-dose EPA (4 g/day) reduced cardiovascular death and MI by 25% in high-risk patients.

• EPA (eicosapentaenoic acid)Scientific

  EPA (eicosapentaenoic acid) has robust clinical evidence supporting cardiovascular benefit, particularly at high doses in high-risk patients. The landmark REDUCE-IT trial demonstrated a 25% reduction in major cardiovascular events with 4 g/day of purified EPA (icosapent ethyl) added to statin therapy. EPA exerts multiple cardioprotective mechanisms including triglyceride reduction, anti-inflammatory action, platelet inhibition, and plaque stabilization. Evidence is strongest for EPA monotherapy versus combined EPA+DHA formulations.

• eucommiaScientific

  Eucommia reduces cardiac workload via its antihypertensive effects (clinical evidence), reduces atherogenic lipids (preclinical), suppresses NLRP3 inflammasome activity in myocardium-relevant cells, and improves endothelial function (clinical FMD data). These indirect but multi-level effects support overall cardiac protection.

• fava beanScientific

  Fava beans support heart health through LDL-cholesterol reduction (via soluble fiber), blood pressure regulation (via potassium, magnesium, and L-DOPA-derived nitric oxide), homocysteine reduction (via folate), and antioxidant protection of cardiac endothelium (via polyphenols). Epidemiological and clinical trial data support coronary heart disease risk reduction with regular legume intake.

• ferulic acidScientific

  Ferulic acid exerts direct cardioprotective effects by improving myocardial function in hypertensive models, reducing cardiac oxidative stress, and lowering circulating cardiovascular risk markers in a human RCT. Animal studies show FA improved heart structure and function in hypertensive rats. Sodium ferulate (FA's salt) has clinical use in China for cardiac conditions.

• fisetinScientific

  Fisetin protects cardiac tissue from HFD-induced dysfunction, diabetic cardiomyopathy, and metabolic-stress injury in rodent models through anti-inflammatory, antioxidant, and anti-fibrotic mechanisms acting on cardiomyocytes and cardiac signaling pathways.

• fish oilScientific

  Fish oil, rich in EPA and DHA omega-3 fatty acids, has extensive clinical trial evidence supporting cardiovascular benefits. Multiple large RCTs and meta-analyses demonstrate reductions in myocardial infarction, cardiovascular mortality, and coronary heart disease events, particularly in high-risk populations. Benefits appear dose-dependent and strongest in secondary prevention settings, though results vary by formulation and patient population.

• flaxseedScientific

  Flaxseed has substantial clinical evidence supporting cardiovascular benefits, primarily through blood pressure reduction and LDL cholesterol lowering. Its three main bioactive components—alpha-linolenic acid (ALA), lignans, and soluble fiber—each contribute through distinct mechanisms. Multiple meta-analyses of randomized controlled trials confirm statistically significant reductions in both systolic and diastolic blood pressure, as well as modest improvements in lipid profiles.

• folic acidScientific

  Folic acid has well-documented clinical relevance to cardiovascular health, primarily through its role in lowering plasma homocysteine—an independent risk factor for cardiovascular disease. Multiple large meta-analyses of randomized controlled trials (RCTs) demonstrate a significant reduction in stroke risk with supplementation, though effects on coronary heart disease and overall cardiovascular mortality are less consistent. Secondary mechanisms include improved endothelial nitric oxide bioavailability, independent of homocysteine lowering. Benefits appear most pronounced in individuals with low baseline folate or elevated homocysteine.

• forskohlii rootScientific

  Forskolin is a positive inotrope and positive chronotrope in cardiac muscle via cAMP elevation, and has been used intravenously in clinical trials for heart failure. A water-soluble derivative (colforsin daropate) is approved in Japan for acute heart failure.

• forsythiaScientific

  Forsythia acts on the heart meridian in TCM and its active compounds—forsythiasides—have documented cardiovascular protective properties in preclinical studies. A dedicated Frontiers in Cardiovascular Medicine review (2022) covers forsythiaside cardiovascular protection. Mechanistic actions include antioxidant protection of cardiac tissue and NF-κB/Nrf2 pathway modulation.

• gamma oryzanolScientific

  Gamma oryzanol protects cardiac structure and function in animal models of metabolic stress, preventing atrial and ventricular hypertrophy and functional deterioration. It also attenuates aortic valve calcification in vitro. Its lipid-lowering effects reduce the lipid-related cardiac disease burden.

• ganodermaScientific

  Preclinical mouse studies show Ganoderma spore oil normalises cardiac function in a pressure-overload model, reducing LV hypertrophy and correcting ejection fraction. Human RCT data show a significant reduction in heart rate. Triterpenes provide cardioprotective mechanisms via ACE inhibition and anti-platelet activity.

• garbanzo beanScientific

  Garbanzo beans support cardiac function directly through magnesium (which regulates heart rhythm and reduces arrhythmia risk), potassium (which opposes sympathetic cardiac stimulation and reduces hypertension), folate (reducing homocysteine-mediated endothelial damage), and omega-3 and omega-6 fatty acids that reduce cardiac inflammation. Meta-analyses link regular pulse/chickpea consumption to reductions in coronary heart disease risk.

• garlicScientific

  Multiple randomized controlled trials and meta-analyses provide clinical evidence that garlic supplementation modestly reduces systolic and diastolic blood pressure, lowers total cholesterol and LDL, inhibits platelet aggregation, and reduces inflammatory markers. The primary active compounds are organosulfur molecules (allicin and its polysulfide metabolites) that generate hydrogen sulfide, a vasodilatory cell-signaling molecule. Evidence is most consistent for hypertensive populations; results in normotensive individuals and for hard cardiovascular endpoints (infarction, stroke, death) remain unestablished.

• garlic bulbScientific

  Garlic benefits the heart through antihypertensive effects (reducing cardiac afterload), lipid-lowering (reducing atherosclerotic plaque burden), antiplatelet activity (reducing thrombotic risk), and direct cardiac antioxidant effects. Black garlic has been shown to improve heart function and circulating antioxidant levels in coronary heart disease patients.

• gastrodiaScientific

  Gastrodin protects against hypertensive cardiac injury, reducing myocardial apoptosis, cardiac dysfunction, and pathological cardiac remodeling in animal models. Clinical evidence from China shows gastrodin used as adjunct therapy in cardiovascular disease management.

• genisteinScientific

  Genistein, a soy-derived isoflavone phytoestrogen, has been studied in multiple human RCTs and meta-analyses for its effects on cardiovascular risk factors. Evidence from pooled RCTs shows significant reductions in LDL-cholesterol, total cholesterol, and systolic blood pressure, with the strongest benefits observed in postmenopausal women and those with metabolic syndrome. A pilot RCT also demonstrated improved left ventricular ejection fraction and left atrial function after one year of supplementation. The evidence base, while promising, remains heterogeneous and calls for larger, standardized clinical trials.

• ginkgo bilobaScientific

  Ginkgo biloba has documented cardiovascular mechanisms — including vasorelaxation, antiplatelet activity, antioxidant effects, and improved coronary perfusion — backed by clinical and preclinical studies. However, the largest randomized controlled trial (GEM Study, n=3,069) found no reduction in cardiovascular events, mortality, or coronary heart disease outcomes with EGb 761 vs. placebo. NCCIH similarly concludes ginkgo is not helpful for preventing heart disease. The evidence is 'scientific' in that substantial human clinical trial data exist, but those trials largely do not support clinical benefit for cardiac endpoints.

• ginsengScientific

  Ginseng (Panax ginseng) has documented scientific evidence supporting cardiovascular and cardiac effects, primarily through its bioactive ginsenosides. Preclinical and clinical studies demonstrate cardioprotective, antioxidant, anti-inflammatory, antithrombotic, and vasodilatory mechanisms relevant to coronary heart disease and heart failure. Clinical evidence exists but is limited to small trials and ginseng-containing formulations (e.g., Shenmai/Shenfu injections) used adjunctively, with a paucity of large-scale, well-controlled trials. Overall, experimental evidence is robust while clinical evidence remains preliminary.

• glucomannanScientific

  Glucomannan was studied in a double-blind trial specifically in post-infarction cardiac rehabilitation patients, showing significant reductions in body weight and total cholesterol. The totality of its lipid-lowering and glycemic effects makes it relevant to reducing cardiac risk burden. Its systolic blood pressure reduction in one RCT also directly affects cardiac workload.

• gooseberryScientific

  Multiple clinical RCTs document amla's direct cardioprotective effects: reduced atherogenic lipid fractions, improved endothelial function, reduced arterial stiffness, anti-platelet activity, and blood pressure reduction. A systematic review specifically focused on amla's cardiovascular (including heart) pharmacology has been published.

• grapeScientific

  Multiple human clinical trials and meta-analyses demonstrate that grapes and grape-derived products (whole fruit, juice, seed extract, and polyphenol extracts) exert measurable cardioprotective effects. Key documented benefits include reductions in systolic blood pressure, inhibition of platelet aggregation, decreased LDL oxidation, improved endothelial function, and reduced inflammatory markers. The primary bioactive compounds responsible are polyphenols—resveratrol, proanthocyanidins (OPCs), and flavonoids—found across the whole fruit, skin, and seeds. Evidence strength is moderate, with heterogeneity across trials and some outcomes showing only small effect sizes.

• green teaScientific

  Green tea has substantial clinical and epidemiological evidence supporting cardiovascular benefit. Multiple RCT-based meta-analyses show modest but statistically significant reductions in LDL cholesterol, total cholesterol, and systolic blood pressure. Large cohort studies in Asian populations link regular green tea consumption to meaningfully lower CVD mortality. The primary active constituents are catechins, especially epigallocatechin gallate (EGCG), which act via antioxidant, anti-inflammatory, and anti-atherosclerotic mechanisms.

• guaranaScientific

  Guarana affects the heart directly via its methylxanthine content — caffeine and theobromine influence heart rate and cardiac contractility — and indirectly through antiplatelet and LDL-oxidation-reducing properties that protect against atherosclerosis. Epidemiological data show lower hypertension and cardiac risk factor prevalence in habitual users. Case reports also note arrhythmia risk at high doses.

• guggulScientific

  The heart is a primary target organ of guggul's documented actions, including cholesterol modulation, anti-thrombotic effects, and prevention of LDL oxidation and platelet adhesiveness in coronary artery disease patients. A clinical trial specifically in ischemic heart disease and stroke patients has been conducted. Effects are mixed across trials.

• hawthornScientific

  Hawthorn (Crataegus spp.) has substantial human clinical evidence supporting its use for cardiovascular conditions, particularly mild-to-moderate heart failure. Multiple placebo-controlled trials and a Cochrane systematic review report improvements in exercise tolerance and symptom control in NYHA class I–III heart failure patients. The large SPICE trial (n=2,681) found the standardized extract WS 1442 was safe as an add-on therapy, though it did not significantly reduce the primary composite cardiac endpoint in advanced heart failure. Germany's Commission E has formally approved hawthorn leaf-with-flower extracts for NYHA class II heart failure.

• hesperetinScientific

  Hesperetin and hesperidin directly protect the heart from oxidative stress, inflammation, and drug-induced cardiotoxicity. Systematic reviews confirm cardioprotective effects including mitigation of myocardial infarction-related damage and modulation of cardiovascular risk factors in human trials.

• hesperidinScientific

  Hesperidin protects the heart against hypertension-induced damage, drug-induced cardiotoxicity, and myocardial inflammation. It restores heart-weight ratios and cardiac hemodynamic parameters in hypertensive models, reduces myocardial inflammatory and oxidative stress markers, and improves cardiac output parameters in preclinical studies. Clinical RCTs confirm improvements in cardiovascular risk factors.

• hibiscusScientific

  Hibiscus sabdariffa (roselle) has meaningful clinical evidence supporting cardiovascular benefit, primarily through blood pressure reduction. Multiple randomized controlled trials and meta-analyses show statistically significant reductions in systolic blood pressure versus placebo. The NIH's NCCIH recognizes hibiscus among dietary interventions that may help reduce blood pressure in people with hypertension. Evidence also extends to modest improvements in lipid profiles.

• HMR lignanScientific

  HMR reduces LDL oxidation, ICAM-1/VCAM-1 vascular adhesion, and dyslipidemia in preclinical models — all factors directly relevant to myocardial protection from atherogenesis. Epidemiological data from Finnish cohort studies associate high serum enterolactone with reduced acute coronary event risk. No human cardiac endpoint RCT with HMRlignan exists.

• honeyScientific

  Honey reduces key cardiometabolic risk factors associated with heart disease—including LDL-C, triglycerides, CRP, and fasting blood glucose—in controlled human trials. Its antioxidant polyphenols protect against LDL oxidation and endothelial dysfunction. GRADE-assessed meta-analyses confirm honey's modest but statistically significant cardioprotective effects.

• horehoundScientific

  Rodent studies document antihypertensive, vasodilatory, and antiarrhythmic properties, with marrubenol characterised as an L-type calcium channel blocker. In vitro studies show inhibition of LDL oxidation relevant to atherosclerosis prevention. Drugs.com's 2025 review confirms cardiovascular pharmacology as the most studied animal research area for horehound.

• huckleberryScientific

  Vaccinium anthocyanins have been shown in multiple human RCTs to reduce cardiovascular risk factors including dyslipidemia, inflammation, and oxidative stress relevant to cardiac health. Huckleberry shares the anthocyanoside profile responsible for these effects. The Vaccinium berry genus has one of the strongest phytochemical cases for heart protection among fruits.

• inositol nicotinateScientific

  IHN's conversion to niacin directly affects lipid markers most relevant to coronary heart disease: LDL, HDL, triglycerides, and VLDL. The 2019 Circulation abstract explicitly framed IHN as an alternative to niacin for dyslipidemia prevention of cardiovascular disease. However, IHN has not been tested in dedicated cardiac outcome trials, and at large niacin doses, caution is required in patients with unstable angina due to arrhythmia risk.

• inula racemosaScientific

  The heart is the most pharmacologically investigated organ target of I. racemosa. Animal studies demonstrate protection against ischemic cardiac injury, restoration of cardiac antioxidants, prevention of myocyte enzyme leakage, and beta-adrenergic modulation. Human data include a clinical report on angina and ECG improvement in IHD patients.

• jiaogulanScientific

  Jiaogulan protects cardiomyocytes from ischemia-reperfusion injury by inhibiting inflammatory protein expression, and supports heart function by reducing cardiac workload through vasodilation, blood pressure reduction, and favorable lipid effects. Multiple clinical and mechanistic studies support this relationship.

• kaleScientific

  Kale directly improves cardiac risk factors including LDL, HDL, blood pressure, and atherogenic index in human clinical trials. Quercetin and kaempferol in kale reduce LDL oxidation and improve endothelial function. Vitamin K1 modulates vascular calcification pathways relevant to coronary artery health. The Kim et al. 2008 trial showed significant coronary artery disease risk factor improvements with kale juice.

• knotweedScientific

  Knotweed's polyphenols support cardiac function through multiple documented mechanisms: improving flow-mediated dilation in RCTs, lowering blood pressure (meta-analysis), reducing triglycerides, inhibiting LDL oxidation, and anti-platelet effects. Polydatin from PC showed antihyperlipidemic and membrane-stabilizing cardioprotective effects. TCM lists Hu Zhang as entering the heart meridian.

• krill oilScientific

  Krill oil delivers EPA and DHA as phospholipid esters, which supports cardiovascular health primarily by lowering elevated triglyceride levels and raising HDL cholesterol. Multiple randomized controlled trials and a 2023 systematic review and meta-analysis confirm these lipid-modifying effects. Evidence for reducing hard cardiovascular events (e.g., heart attacks) directly attributable to krill oil specifically, as opposed to omega-3s broadly, remains limited.

• kudzuScientific

  The heart is the most extensively studied organ target for puerarin from kudzu root. Clinical and preclinical evidence documents puerarin's cardioprotective effects in angina, myocardial infarction, cardiac hypertrophy, and arrhythmia. TCM has used kudzu for heart conditions for over 2,000 years.

• L-arginineScientific

  L-arginine is the sole substrate for endothelial nitric oxide (NO) synthesis, making it directly relevant to cardiac and vascular function. Multiple randomized controlled trials and meta-analyses document improvements in endothelial function, blood pressure, coronary microcirculation, and hemodynamic parameters in heart failure. Evidence is strongest for endothelial and hemodynamic outcomes; its impact on hard cardiac endpoints such as mortality remains inconclusive.

• l-carnitineScientific

  L-carnitine has robust clinical evidence supporting its role in cardiac health, primarily through facilitating mitochondrial fatty acid oxidation — the heart's dominant energy pathway. Multiple meta-analyses of RCTs show significant reductions in all-cause mortality, ventricular arrhythmias, and angina following acute myocardial infarction. In chronic heart failure, L-carnitine improves left ventricular ejection fraction and cardiac output, though mortality benefit in this setting is less established.

• L-citrullineScientific

  L-Citrulline has well-documented, clinically studied effects on cardiovascular function. As a precursor to L-arginine, it enhances nitric oxide (NO) synthesis, promoting vasodilation and blood pressure reduction. Meta-analyses of randomized controlled trials show modest but statistically significant reductions in both systolic and diastolic blood pressure. Clinical studies also indicate benefits for endothelial function, arterial stiffness, and cardiac performance in heart failure patients.

• LA (linoleic acid)Scientific

  Higher LA intake and blood levels are associated with reduced risk of coronary heart disease in dose-response meta-analyses of prospective cohort studies. LA lowers LDL cholesterol in controlled trials and is inversely associated with cardiac inflammatory biomarkers. Current cardiological dietary guidelines (AHA) recommend LA as a replacement for saturated fat to reduce CHD risk.

• lemon balmScientific

  Lemon balm directly affects cardiac function: a human RCT demonstrated reduction in palpitation frequency; a meta-analysis showed systolic blood pressure reduction; and animal ECG studies characterised effects on cardiac conduction. ACE inhibitory activity of rosmarinic acid, GABAergic autonomic calming, and antiarrhythmic animal data converge on a cardiac-specific evidence base.

• lophatherum leafScientific

  Preclinical studies show L. gracile extract has vasorelaxant activity in rat aortic tissue via endothelium-dependent NO-cGMP signaling, and antiplatelet activity has been documented in vitro. Constituent flavonoids confer myocardial protection in animal models. Modern pharmacological reviews categorize cardioprotective activity among the herb's primary pharmacological effects.

• lotus seedScientific

  Lotus seed embryo alkaloids (neferine, liensinine, isoliensinine) directly protect the heart through anti-arrhythmic, antihypertensive, and antioxidant mechanisms in animal models. TCM assigns lotus seed to the Heart meridian as a primary organ target.

• luteinScientific

  Higher lutein intake and blood concentrations are associated with significantly lower risk of coronary heart disease in epidemiological meta-analyses, and lutein reduces inflammatory markers implicated in cardiac pathology. Clinical studies in CAD patients show lutein inversely correlates with IL-6 and can reduce IL-6, LDL, and triglycerides with supplementation. Animal data further support direct cardioprotection via antioxidant and anti-apoptotic mechanisms.

• luteolinScientific

  Luteolin protects cardiomyocytes from hypertrophy, fibrosis, and failure in preclinical models, with PPARγ identified as its direct cardiac target. It also reduces hyperlipidemia-induced cardiac damage and is supported by human combination nutraceutical RCT data.

• lycopeneScientific

  Lycopene, the carotenoid pigment predominant in tomatoes, has substantial epidemiological and clinical trial evidence linking higher intake and tissue levels to reduced cardiovascular disease risk. Proposed mechanisms include antioxidant activity, inhibition of LDL oxidation and cholesterol synthesis, anti-inflammatory and anti-atherosclerotic effects, and improvements in endothelial function. Meta-analyses of intervention trials show dose-dependent reductions in LDL cholesterol and systolic blood pressure at doses ≥25 mg/day, though overall pooled results across all trials remain conflicting due to high heterogeneity in study design and lycopene dose.

• macadamiaScientific

  The heart is directly benefited by macadamia nut consumption through favorable modification of lipid risk factors for coronary artery disease. Multiple RCTs show reductions in total cholesterol and LDL-C, with improved atherogenic ratios, reducing atherosclerotic plaque risk to coronary vessels. Reviews link regular macadamia nut consumption to reduced coronary artery disease risk.

• magnesiumScientific

  Magnesium has well-documented, mechanistically grounded roles in cardiac function, supported by extensive clinical and epidemiological evidence. It regulates cardiac ion channels, myocardial conduction, and contraction, and hypomagnesemia is directly linked to arrhythmias and increased cardiovascular risk. Large meta-analyses and prospective cohort studies consistently associate higher magnesium levels with lower risks of coronary heart disease, atrial fibrillation, and heart failure. Intravenous magnesium is clinically indicated for specific arrhythmias such as Torsades de Pointes, though evidence for routine supplementation in broader cardiac prevention remains inconsistent.

• mangoScientific

  Multiple human RCTs document mango's beneficial effects on heart-relevant biomarkers including LDL cholesterol, total cholesterol, blood pressure, and PAI-1. A 2025 RCT in postmenopausal women found significant reductions in blood pressure and LDL within 2 weeks. Mangiferin has demonstrated cardioprotective effects in animal models.

• maqui berryScientific

  Maqui berry anthocyanins directly protect the cardiovascular system, demonstrating reductions in atherogenic LDL oxidation in a double-blind RCT and improving LDL/HDL profiles in a clinical trial. Large epidemiological studies on dietary anthocyanin intake associate higher consumption with 32% reduced heart attack risk. Maqui's delphinidins also reduce vascular inflammation and support endothelial function.

• marjoramScientific

  Marjoram extract has shown direct cardioprotective activity in rat cardiac injury models, reducing myocardial damage, normalizing cardiac enzymes, and decreasing inflammatory and oxidative markers in heart tissue.

• melatoninScientific

  Melatonin has documented cardioprotective effects supported by human clinical trials and systematic reviews. Evidence spans blood pressure reduction, protection against ischemia-reperfusion injury, and improved outcomes in heart failure. Clinical trial data remain preliminary, with most robust human evidence coming from small-to-moderate RCTs, but the mechanistic basis is well-characterized.

• methylcobalaminScientific

  The heart is adversely affected by B12/MeCbl deficiency through hyperhomocysteinemia-mediated endothelial and myocardial damage. In inborn errors of cobalamin metabolism (cblC), severe cardiac manifestations including pulmonary hypertension and cardiomyopathy are documented. MeCbl-containing B-vitamin therapy is used to manage homocysteine-mediated cardiac risk.

• millet seedScientific

  Millet seed consumption reduces multiple direct cardiac risk factors simultaneously—cholesterol, triglycerides, BMI, and blood pressure—in meta-analytic human evidence. Millet polyphenols reduce vascular oxidative stress and ACE-inhibitory peptides lower cardiac afterload. Magnesium content supports myocardial electrophysiology.

• morindaScientific

  M. citrifolia's cardiovascular effects—antihypertensive (via eNOS/AMPK pathway), antidyslipidaemic (clinical RCT evidence), anti-AGE endothelial protection, and anti-inflammatory hs-CRP reduction—collectively support cardiac health. Traditional documentation for noni in heart-related conditions is extensive.

• morusScientific

  Morus extracts protect cardiac tissue from inflammation and hypertrophic changes in animal models, and human RCTs confirm reductions in cardiovascular risk factors including blood pressure, lipids, and CRP. A mouse study showed mulberry leaf extract prevented left ventricular hypertrophy via anti-inflammatory mechanisms.

• motherwortScientific

  Motherwort has direct pharmacological effects on the heart including negative chronotropy, cardioprotection, and mitochondrial antioxidant support. The German Commission E and EMA authorize it for cardiac complaints. Human pilot data shows heart rate reduction and improved cardiac function. Preclinical evidence confirms antianginal, antiarrhythmic, and cardioprotective properties.

• mustardScientific

  Mustard seed's omega-3 fatty acids, plant sterols, and isothiocyanates provide direct cardioprotective effects including LDL-C reduction, anti-inflammatory vascular protection, and lipid profile improvement documented in animal models and preliminary human data. The PMC 2022 review specifically synthesizes mustard's role in reducing cardiovascular disease risk.

• myrobalanScientific

  TC protects cardiac tissue from injury in animal models and demonstrated improved endothelial function in a 12-week human RCT in diabetic patients. Traditional Ayurvedic medicine classifies TC as a cardiotonic and heart-stimulating herb used in heart disease.

• naringinScientific

  Naringin protects the myocardium from ischemia-reperfusion injury, reduces infarct size, preserves cardiac function, and attenuates diabetic and sepsis-induced cardiomyopathy in animal models. A 2025 systematic review confirmed these effects across 62 studies. Limited human RCT evidence shows improved cardiometabolic parameters over 90 days.

• nattokinaseScientific

  Nattokinase is a fibrinolytic serine protease derived from fermented soybeans (natto) with multiple documented mechanisms relevant to cardiovascular health, including direct clot dissolution, antihypertensive activity, and anti-atherosclerotic effects. Multiple RCTs and a 2023 systematic review and meta-analysis of six high-quality trials (546 participants) support its use as adjunctive therapy for hypertension. Evidence for lipid-lowering is dose-dependent and more mixed. Overall, the scientific basis for nattokinase's cardiovascular effects is well-established at the clinical level, though effect sizes are modest.

• nattozimesScientific

  Nattokinase supports cardiac health through antihypertensive, fibrinolytic, and lipid-modulating mechanisms that reduce key risk factors for myocardial infarction and other cardiac events. Epidemiological data link high natto consumption to reduced ischemic heart disease mortality in Japanese populations.

• nicotinamide ribosideScientific

  NR has been directly tested in human heart failure patients, demonstrating safety and elevation of whole-blood NAD+ at 2 g/day over 12 weeks, with correlations to improved mitochondrial respiration and reduced inflammation in HFrEF patients. Mechanistic human trials are assessing direct myocardial NAD+ levels. Animal studies robustly demonstrate NR restores myocardial NAD+ and preserves cardiac function in cardiomyopathy models.

• oatScientific

  Oat β-glucan reduces LDL cholesterol, non-HDL cholesterol, and apolipoprotein B—all established coronary heart disease risk markers. Avenanthramides reduce cardiac-relevant arterial inflammation. FDA and EFSA health claims for oat and heart disease are among the most established dietary supplement claims.

• oleanolic acidScientific

  OA protects cardiac tissue from hyperglycemia-induced contractile dysfunction, ischemia-reperfusion injury, and apoptosis in cardiomyoblasts and intact rat hearts. It upregulates myocardial antioxidant defenses and reduces cardiac oxidative stress and HBP pathway activation.

• oleic acidScientific

  Oleic acid is directly relevant to heart organ health through its LDL-lowering, HDL-raising, and anti-inflammatory effects. The FDA recognises a qualified health claim linking dietary oleic acid intake to reduced coronary heart disease risk. Multiple RCTs confirm beneficial lipid profile changes, and the MESA cohort study (n=6,568) provides data on oleic acid and heart failure outcomes.

• oliveScientific

  Olive leaf extract has clinical evidence for direct cardiac risk factor modification: blood pressure reduction, LDL cholesterol lowering, triglyceride reduction, antiplatelet activity, and protection of blood lipids from oxidative damage. These mechanistically converge on reducing atherosclerosis, myocardial infarction, and stroke risk. Multiple RCTs and a 2022 meta-analysis confirm these effects.

• olive oilScientific

  Olive oil directly benefits cardiac physiology by reducing atherosclerotic plaque development, improving myocardial antioxidant status, lowering cardiac risk biomarkers (LDL, CRP, NT-proBNP), and inhibiting endothelial dysfunction. PREDIMED and large prospective cohort data confirm olive oil consumption reduces cardiovascular mortality.

• omega-3 fatty acidsScientific

  Omega-3 fatty acids (EPA and DHA) have extensive clinical evidence supporting cardiovascular benefit, most consistently for reducing coronary heart disease mortality, sudden cardiac death, and triglyceride levels. Large RCTs such as REDUCE-IT and VITAL have demonstrated significant reductions in major cardiovascular events and fatal heart attacks. Evidence is strongest at pharmacological doses (≥4 g/day EPA) and in high-risk populations, while results across mixed EPA/DHA formulations remain more heterogeneous.

• omega-6 fatty acidsScientific

  Linoleic acid (LA) and other omega-6 PUFAs have documented effects on cardiac risk factors, including modest total cholesterol reduction and improved lipoprotein profiles when substituted for saturated fat. Longitudinal cohort studies associate higher LA biomarker status with lower incident coronary heart disease. However, no omega-6 supplementation RCTs have tested hard cardiac endpoints (MI, cardiac mortality). The AHA supports 5–10% of energy from omega-6 for cardiovascular protection.

• onionScientific

  Onion protects the heart through reduction of cardiovascular risk factors established across multiple RCTs: lowering LDL cholesterol and total cholesterol, reducing blood pressure, inhibiting platelet aggregation (reducing thrombotic risk), and decreasing systemic inflammation. These combined effects reduce the major contributors to coronary artery disease and acute cardiac events.

• ophiopogonScientific

  The heart is the primary target organ of Ophiopogon japonicus research. Cardioprotective effects include protection against ischemia, CHF, doxorubicin toxicity, and arrhythmia, supported by clinical formula studies and extensive preclinical evidence.

• ophiopogon rootScientific

  The heart meridian is one of the three primary organ systems on which ophiopogon root acts in TCM, and this is corroborated by extensive preclinical and clinical data. The herb directly protects cardiomyocytes from ischemic and toxic injury, improves heart function in failure models, and reduces arrhythmia via electrophysiological effects. Clinical evidence via Shengmai/Shenmai injections includes RCTs.

• orangeScientific

  Orange flavonoids—hesperidin and hesperetin—protect the heart from cardiotoxicity, improve lipid profiles, reduce vascular inflammation, and enhance endothelial function. A 2024 systematic review confirmed hesperidin's clinical benefits including reductions in LDL, total cholesterol, and inflammatory markers. Blood orange antioxidants additionally show direct cytoprotective effects on cardiac tissue.

• oryzaScientific

  Rice bran (Oryza sativa) has been shown in animal models to prevent obesity-related cardiac structural and functional impairment by reducing inflammatory cytokines and oxidative stress in myocardial tissue, with γ-oryzanol identified as the primary active compound.

• pantethineScientific

  Pantethine's lipid-lowering effects documented across more than 28 controlled trials directly benefit the heart by reducing key modifiable risk factors for coronary artery disease. CoA is an essential cofactor for cardiac energy metabolism; a 2025 published case report documented pantethine therapy rescuing end-stage heart failure in an infant with genetically impaired CoA biosynthesis. These together establish heart as a primary target organ.

• peanutScientific

  Peanuts favourably alter cardiac risk factors including LDL cholesterol, HDL cholesterol, triglycerides, and the LDL/HDL ratio through their MUFA, phytosterol, fibre, and resveratrol content. An FDA qualified health claim acknowledges peanuts' role in heart disease risk reduction. Multiple RCTs confirm the lipid-lowering mechanism.

• pearScientific

  Pear polyphenols — catechins, chlorogenic acid, quercetin — protect cardiac tissue through antioxidant, anti-inflammatory, and LDL-lowering mechanisms. Epidemiological cohort data link pear/apple intake to reduced cardiovascular mortality. Catechins from pears have cardioprotective effects demonstrated in studies of catechin-rich foods. Anti-atherogenic properties reduce the long-term burden on cardiac tissue.

• phosphorusScientific

  Elevated serum phosphorus is associated with left ventricular hypertrophy, vascular calcification, coronary artery disease, cardiac arrhythmia risk, and increased cardiovascular mortality—particularly in CKD but also in the general population. High dietary phosphorus was found significantly associated with increased left ventricular mass.

• phytosterolsScientific

  Phytosterols have robust clinical evidence for reducing LDL cholesterol, a primary cardiovascular risk factor. They act by competing with cholesterol for intestinal micellar solubilization and NPC1L1-mediated absorption, thereby reducing circulating LDL-C. At doses of ≥2 g/day, multiple meta-analyses of RCTs consistently demonstrate meaningful LDL reductions, and both the FDA and EFSA have authorized cardiovascular risk-reduction health claims for phytosterol-enriched foods. No RCT with hard cardiovascular outcomes (heart attacks, mortality) has yet been completed.

• plant sterolsScientific

  Plant sterols are among the most extensively studied natural interventions for cardiovascular risk reduction. Their primary mechanism is competitive inhibition of intestinal cholesterol absorption, reducing LDL-C by approximately 8–10% at a dose of 2 g/day. The ESC/EAS 2019 dyslipidemia guidelines recommend plant sterols as an adjunct to lifestyle modification for blood cholesterol lowering. Effects are additive with statin therapy.

• policosanolScientific

  Policosanol, a mixture of long-chain aliphatic alcohols primarily derived from sugarcane wax, has been studied in multiple human clinical trials for cardiovascular-relevant effects including lipid modification, blood pressure reduction, and antiplatelet activity. Early Cuban trials reported substantial LDL-lowering, but independent trials conducted in Germany, North America, and elsewhere largely failed to replicate these findings, and EFSA concluded the LDL-lowering evidence was inconsistent. More recent randomized controlled trials in Asian populations (Korean, Japanese) using standardized Cuban-derived policosanol have shown modest but statistically significant reductions in blood pressure and improvements in HDL particle function.

• pomegranateScientific

  Pomegranate has robust clinical evidence for direct cardiac benefit: reducing blood pressure, lowering LDL and total cholesterol, protecting lipoproteins from oxidation, improving endothelial function, and attenuating atherosclerosis. Multiple RCTs and meta-analyses document these effects on cardiac risk factors.

• potassiumScientific

  Potassium is essential for normal cardiac electrophysiology, governing action potential repolarization through multiple K+ channel subtypes. Both hypo- and hyperkalemia disrupt cardiac rhythm and are clinically significant causes of arrhythmia. Multiple RCTs and meta-analyses document potassium's effects on cardiac-relevant endpoints including blood pressure and CVD outcomes.

• propionyl-L-carnitineScientific

  Propionyl-L-Carnitine (PLC) has substantial human clinical evidence supporting its use in heart-related conditions, including chronic heart failure, stable angina, and ischemic heart disease. Multiple randomized controlled trials demonstrate improvements in exercise capacity, oxygen consumption, and ventricular function. Its primary mechanisms involve enhanced mitochondrial fatty acid oxidation, anaplerotic support of the Krebs cycle during ischemia/hypoxia, antioxidant activity, and correction of Ca²⁺-handling defects in the failing myocardium.

• pruneScientific

  Clinical trial data in postmenopausal women and older men show prune consumption reduces inflammatory endothelial risk markers, improves HDL cholesterol, and lowers LDL—key determinants of cardiac event risk. Prune phenolics inhibit LDL oxidation and suppress NF-κB-mediated vascular inflammation.

• pterocarpus marsupiumScientific

  P. marsupium is documented as a cardiac tonic in Ayurveda and has demonstrated cardioprotective effects in a high-fat diet atherosclerosis preclinical model, including reduced aortic lipid infiltration and improved lipid parameters.

• purslaneScientific

  Meta-analyses of RCTs demonstrate purslane significantly improves multiple cardiac risk biomarkers: reducing triglycerides, total cholesterol, and CRP while increasing HDL-C. Its highest-among-land-plants omega-3 content and potassium provide the primary cardioprotective mechanisms. Blood pressure reductions further support direct cardiac benefit.

• pyrroloquinoline disodium saltScientific

  PQQ is directly cardioprotective in preclinical models, halving myocardial infarct size and preserving cardiac mitochondrial function in ischemia/reperfusion studies. Human evidence shows PQQ reduces cardiovascular biomarkers (CRP, IL-6, lipid peroxides) and a clinical trial examined effects on serum lipids relevant to heart disease.

• quercetinScientific

  Quercetin has substantive human clinical evidence for cardioprotective effects, most robustly demonstrated as reductions in systolic and diastolic blood pressure across multiple randomized controlled trials and meta-analyses. Its core mechanisms include inhibition of LDL oxidation, protection of nitric oxide bioavailability and endothelial function, anti-platelet aggregation activity, and reduction of inflammatory adhesion molecules. Evidence for lipid-profile improvement is less consistent, and most mechanistic detail remains stronger in preclinical than in human studies.

• quinoaScientific

  Clinical trials show quinoa lowers LDL-C, total cholesterol, and triglycerides—lipid parameters directly implicated in atherosclerosis and ischemic heart disease. Quinoa's polyphenols protect LDL from oxidative modification and reduce systemic inflammation. A 12-week trial reported significant CRP reduction, a cardiac risk biomarker. Blood pressure reductions were documented in a 1-year RCT.

• red cloverScientific

  Red clover isoflavones have been specifically studied for cardioprotective effects including arterial compliance and lipid modification in multiple RCTs. The heart as an organ benefits indirectly through reduced vascular resistance, improved arterial elasticity, and favorable lipid profile changes, reducing workload and atherosclerotic risk. Evidence is moderate and primarily in peri/postmenopausal women.

• red yeast riceScientific

  RYR is most strongly evidenced for cardiovascular outcomes. Multiple meta-analyses of RCTs demonstrate significant reductions in LDL-C, total cholesterol, and triglycerides, and a landmark meta-analysis of 7 RCTs (n=10,699 MI patients) showed RYR 1,200 mg/day reduced nonfatal MI by 58%, revascularization by 42%, and sudden death by 29%. A broader meta-analysis of 30 RCTs found 38% lower all-cause mortality and 46% fewer major adverse cardiovascular events in metabolic syndrome.

• reishi mushroomScientific

  Reishi has been used in TCM specifically for heart-related symptoms including palpitations and chest tightness. Human evidence includes symptom relief in coronary artery disease. Preclinical data show anti-platelet, antioxidative LDL protection, and antihyperlipidaemic effects. Cochrane review (2015) found no significant cardiovascular risk factor reduction in RCTs, representing the highest-quality negative human finding.

• resveratrolScientific

  Resveratrol, a stilbene polyphenol found in grapes and red wine, has been studied extensively for cardioprotective effects. Preclinical evidence is robust, showing benefits against atherosclerosis, ischemic heart disease, hypertension, and heart failure. A number of small human RCTs have reported improvements in left ventricular function, endothelial function, and LDL-cholesterol in patients with coronary artery disease and heart failure. However, clinical evidence remains limited and inconsistent, and resveratrol has not been established as a standard-of-care intervention.

• rhodiolaScientific

  Rhodiola rosea demonstrates cardioprotective pharmacology including prevention of stress-induced cardiac damage, reduction of myocardial catecholamine levels, anti-arrhythmic effects via mu-opioid receptor activation, and improvement of cardiac function markers. A 2025 systematic review and meta-analysis documented benefits in HFrEF patients using standardized Rhodiola injection in China.

• rhubarbScientific

  Rhubarb's active compounds protect the heart through lipid-lowering, antioxidant, and anti-inflammatory mechanisms. Emodin has been shown to mitigate diabetic cardiomyopathy through NLRP3 inflammasome inhibition. Clinical trial evidence shows rhubarb reduces cardiovascular risk factors (LDL, triglycerides) in human subjects.

• roseScientific

  Rosehip supports heart health through multiple documented mechanisms: reductions in LDL oxidation, blood pressure lowering via ACE inhibition, and anti-inflammatory cardioprotection. Clinical RCTs and systematic reviews confirm cardiovascular risk factor reductions. Traditional Persian medicine formally categorizes Rosa damascena as a heart tonic.

• rutinScientific

  Human RCTs show rutin reduces blood pressure parameters in diabetic patients. Animal studies show improved ECG parameters, reduced infarct size, and restored cardiac antioxidant enzyme levels after myocardial injury. Rutin's antithrombotic and lipid-lowering actions add indirect cardiac protection.

• safflowerScientific

  Safflower Yellow (SY) and its key component HSYA have documented cardioprotective effects, including protection of cardiomyocytes against ischemia and LPS-induced apoptosis. In dogs, safflower injections retard myocardial injury following infarction. Network pharmacology and in vitro studies link safflower's active compounds to the FoxO signaling pathway and Bcl-2/Bax regulation in cardiac cells. SY is approved by China's FDA for cardiovascular indications.

• saffronScientific

  Saffron demonstrates direct cardioprotective effects at the organ level, including protection of myocardial tissue against ischemia-reperfusion injury in preclinical models, improvement of lipid profiles in coronary artery disease patients, and reduction of cardiovascular risk factors confirmed across 32 RCTs. Its carotenoid constituents protect vascular endothelium and cardiac myocytes from oxidative damage.

• salvianolic acidScientific

  Salvianolic acid (primarily forms A and B), the main water-soluble active compounds from Salvia miltiorrhiza (Danshen), has extensive preclinical evidence for cardioprotection, covering myocardial ischemia-reperfusion injury, heart failure, cardiac fibrosis, and pressure-overload-induced dysfunction. Multiple mechanisms have been characterized in animal and cell models, including antioxidant, anti-inflammatory, and anti-fibrotic actions. Early-phase human clinical trials have confirmed safety and tolerability, with further efficacy trials underway.

• schisandraScientific

  Schisandra protects against doxorubicin-induced cardiotoxicity and its lignans reduce cardiac inflammation and oxidative stress across preclinical studies. Clinical research includes congestive heart failure. The 2016 menopausal RCT demonstrated significant reduction in heart palpitations. TCM lists the heart meridian as a direct target organ.

• schisandrinsScientific

  Schisandrin B exerts direct cardioprotective effects in multiple preclinical models, including protection against drug-induced cardiotoxicity, inhibition of atrial fibrosis, and mitochondrial-protective actions in cardiac tissue. These effects are mechanistically documented and replicated across multiple research groups.

• scrophularia rootScientific

  The heart is a directly studied organ target of Scrophularia root pharmacology. Preclinical studies demonstrate anti-ventricular remodelling, cardiomyocyte protection, prevention of myocardial hypertrophy, and blood pressure reduction. Small doses are described as cardiotonic in TCM, with higher doses having inhibitory effects.

• secoisolariciresinol diglucosideScientific

  SDG directly protects the myocardium from oxidative stress, iron-overload injury, pulmonary hypertension–driven hypertrophy, ischemia-reperfusion damage, and diet-induced fibrosis. Pre-treatment with SDG in PAH rats reduced right ventricular hypertrophy, ROS, lipid peroxidation, and cardiac enzyme elevation. In H9c2 cardiomyocytes, SDG abrogated iron-induced apoptosis and inflammatory cytokine expression.

• seleniumScientific

  Selenium is essential for cardiac health, evidenced most dramatically by Keshan disease — an endemic dilated cardiomyopathy caused by severe selenium deficiency in humans. Selenoproteins protect cardiomyocytes from oxidative stress and are required for normal cardiac muscle function. The KiSel-10 RCT demonstrated significantly reduced cardiovascular mortality with selenium plus CoQ10 supplementation in elderly low-selenium individuals over more than 5 years of follow-up.

• sesameScientific

  As the central organ of the cardiovascular system, the heart benefits from sesame's blood pressure reduction, lipid-lowering, anti-inflammatory, and antioxidant effects. Multiple RCT meta-analyses confirm reductions in SBP (~7.8 mmHg), LDL-C (~29.7 mg/dL), triglycerides (~33.5 mg/dL), and inflammatory markers — all major drivers of cardiac disease and left ventricular hypertrophy.

• sitostanolScientific

  By reducing LDL cholesterol, sitostanol-based stanols address the primary lipid risk factor for coronary artery disease. Trials include populations with established coronary disease. Projected and estimated modelling studies suggest a ~23% reduction in 10-year coronary artery disease incidence from phytostanol ester dietary use. Evidence in post-myocardial infarction women was documented in a Circulation 1997 study.

• sodiumScientific

  Sodium ions play a fundamental electrophysiological role in cardiac function: the rapid influx of Na⁺ through voltage-gated sodium channels generates the phase-0 upstroke of the ventricular action potential, initiating myocardial depolarization and coordinated contraction. Mutations in cardiac sodium channels underlie arrhythmia syndromes including Long-QT syndrome and Brugada syndrome.

• soyScientific

  Soy protein and isoflavones reduce myocardial risk factors: LDL lowering by ~4–10% (meta-analysis of 46 RCTs), blood pressure reduction in hypertensives, anti-inflammatory CRP reduction, and improved lipid profiles in diabetic patients. Soy is included in cardiovascular risk reduction dietary guidelines from multiple major cardiology societies.

• soy isoflavonesScientific

  Soy isoflavones improve multiple cardiac risk factors including LDL cholesterol, total cholesterol, HDL, and blood pressure based on RCT-level evidence. Observational data further link higher isoflavone intake with reduced coronary heart disease risk.

• soybeanScientific

  Soy protein and isoflavones have documented effects on cardiac risk factors including LDL cholesterol, blood pressure, and inflammation. Soy isoflavones have been shown to down-regulate TNF-α in the endothelium of small myocardial arteries in animal models of chronic inflammation. The FDA and Health Canada have approved cardiovascular health claims for soy protein at ≥25 g/day based on LDL-lowering evidence.

• spinachScientific

  Spinach nitrate reduces cardiac afterload through systemic vasodilation and BP reduction. Its antioxidants protect the myocardium from oxidative stress. Folate-mediated homocysteine reduction lowers risk of endothelial damage and cardiac events. These effects are documented in RCTs demonstrating hemodynamic benefits.

• spirulinaScientific

  Multiple RCTs confirm spirulina lowers blood pressure, reduces LDL and triglycerides, raises HDL, and decreases endothelial damage markers in cardiovascular patients. Preclinical data indicate phycocyanin protects against doxorubicin-induced cardiotoxicity by normalizing SOD, CAT, and GPx and reducing mitochondrial damage and lipid peroxidation. A 2025 meta-analysis of RCTs confirmed spirulina's consistent positive effect on cardiovascular risk factors.

• steviaScientific

  Stevia's primary documented effects on the heart are through blood pressure reduction confirmed in human RCTs, and anti-atherosclerotic effects in animal models. Stevioside reduced aortic plaque burden in insulin-resistant mice. No direct human studies of cardiac structure, function, or cardiac-specific endpoints have been conducted.

• steviol glycosidesScientific

  Stevioside at higher doses (750–1500 mg/day) significantly reduces systolic and diastolic blood pressure in RCTs involving patients with mild hypertension. In vitro work shows SG combinations protect cardiac fibroblasts from oxidative stress and enhance antioxidant enzyme activity. Atherosclerotic plaque stabilization has been documented in preclinical models.

• strawberryScientific

  Strawberry consumption is associated with improved cardiac risk biomarkers including reduced atherogenic LDL particles, lower CRP, and lower fasting insulin in multiple RCTs. Epidemiological data including the Iowa Women's Health Study link higher strawberry intake to reduced cardiovascular mortality. Strawberry polyphenols reduce lipid peroxidation and improve nitric oxide bioavailability relevant to cardiac function.

• sulforaphaneScientific

  Sulforaphane protects cardiomyocytes from oxidative stress and inflammatory injury via Nrf2 activation, reduces atherosclerotic risk factors in human trials, and has been studied for cardioprotection in ischemia-reperfusion models. Human biomarker improvements in T2DM trials support cardiovascular benefit.

• sunflowerScientific

  Sunflower seed oil reduces cardiac risk factors (LDL, triglycerides, coagulation factor VIIc) in human RCTs. Helianthus annuus leaf extract attenuated cardiac remodeling and reduced myocardial inflammatory cytokines in an atherosclerosis/myocardial infarction animal model. Vitamin E from sunflower protects cardiac membranes against oxidative stress.

• sunflower oilScientific

  Dietary sunflower oil, particularly the high-oleic variety, has clinical evidence for cholesterol-lowering, reduced LDL oxidation, and favorable cardiovascular risk factor modulation relevant to heart function. The FDA has issued a qualified health claim for oleic acid in high-oleic sunflower oil and reduced coronary heart disease risk. Effects are most evident when replacing saturated fats.

• szechuan lovageScientific

  CX acts directly on the heart through coronary vasodilation, protection against myocardial ischemia-reperfusion injury, reduction of platelet-driven coronary thrombosis, and anti-apoptotic effects on cardiomyocytes. It is associated with the Pericardium meridian in TCM and is a primary herb in cardiovascular formulas used clinically in China.

• tanshinoneScientific

  Tanshinone IIA (Tan IIA), the principal lipophilic bioactive compound from Salvia miltiorrhiza (Danshen), has substantial scientific evidence supporting cardiovascular benefits. Multiple clinical trials and a meta-analysis document its water-soluble derivative (sodium tanshinone IIA sulfonate, STS) reducing major adverse cardiac events, peri-procedural myocardial injury, and improving lipid profiles in coronary heart disease patients. Preclinical evidence consistently shows reduction of myocardial infarct size, cardiac enzyme elevation, and troponin levels via anti-inflammatory, antioxidant, and anti-apoptotic mechanisms. Traditional Chinese Medicine has employed Danshen for heart-related conditions for over a thousand years, providing the historical context from which modern research emerged.

• taurineScientific

  Taurine has robust clinical and epidemiological evidence supporting its role in cardiovascular health. It is the most abundant free amino acid in the heart and has been studied in randomized controlled trials for heart failure, hypertension, and cardiac function. A 2024 meta-analysis of RCTs found statistically significant reductions in heart rate, blood pressure, and NYHA functional class, alongside improvements in left ventricular ejection fraction.

• terminaliaScientific

  T. arjuna has the strongest and most direct clinical evidence of all Terminalia species for the heart organ specifically. Multiple clinical trials document its cardioprotective, inotropic, anti-ischemic, and antihypertrophic effects in heart failure, stable angina, and ischemic cardiomyopathy. It has been used in Ayurveda as the primary cardiac tonic ('hritroga' medicine) for centuries.

• TMG (trimethylglycine)Scientific

  The heart is affected by TMG primarily through systemic homocysteine modulation: elevated homocysteine accelerates coronary artery disease and cardiomyopathy. FDA-approved betaine treats homocystinuria, where the heart is a primary target organ for damage. TMG also functions as an osmolyte protecting cardiomyocytes, and may reduce cardiac oxidative stress via SAMe-dependent pathways. Direct hard cardiac outcome data from TMG trials are not available.

• tocotrienolsScientific

  Clinical evidence supports tocotrienol cardioprotection through improved lipid profiles, anti-inflammatory cytokine reduction, and endothelial support. Tocotrienols inhibit HMG-CoA reductase similarly to statins but via a distinct post-translational mechanism. RCT evidence demonstrates cholesterol, LDL, and inflammatory biomarker reductions relevant to cardiac risk.

• tomatoScientific

  Lycopene from tomatoes supports cardiac health by reducing oxidative stress and inflammation in cardiac tissue, inhibiting LDL oxidation and atherosclerotic plaque formation, and improving cardiac biomarkers in clinical studies. Epidemiological studies show inverse associations between serum lycopene and coronary heart disease mortality.

• trans-geranylgeraniolScientific

  GGOH supports cardiac function as the obligatory upstream precursor for CoQ10, which is especially concentrated in the heart due to its high metabolic demands. By boosting endogenous CoQ10 synthesis, GGOH helps sustain myocardial energy production and antioxidant defense. It also precedes vitamin K2 synthesis, relevant to arterial calcification prevention.

• trans-pterostilbeneScientific

  Pterostilbene protects cardiomyocytes from oxidative injury via AMPK/SIRT1/PGC-1α activation, modulates cholesterol metabolism in cardiac cells through the PCSK9/LDLR pathway, and has demonstrated clinically significant blood pressure reduction in a human RCT.

• trichosanthesScientific

  Trichosanthis Fructus has documented cardioprotective activity including protection against myocardial ischemia, anti-arrhythmic, anti-platelet, and calcium antagonist effects. Pericarpium Trichosanthis injection is in clinical use in China for coronary heart disease and acute myocardial ischemia. Scientific evidence includes pharmacological studies and in vivo animal cardiac models.

• turmericScientific

  Curcumin exerts direct and indirect cardioprotective effects including reduction of atherosclerotic risk factors (LDL-C, blood pressure, CRP, TNF-α), endothelial protection, and anti-inflammatory activity in cardiac tissue. RCTs confirm benefit in patients with diabetes and ASCVD risk. Traditional Ayurvedic use for heart protection is documented.

• ubiquinolScientific

  Cardiac muscle has the highest CoQ10 concentration and energy demand of any tissue, and ubiquinol deficiency is well-documented in heart failure patients. Clinical evidence includes the Q-SYMBIO RCT showing reduced major adverse cardiovascular events with 300 mg/day CoQ10, and a ubiquinol-specific study showing 25–50% ejection fraction improvement in advanced HF. Ubiquinol is preferred in severe HF due to superior absorption.

• vitamin B1Scientific

  The heart is among the organs most sensitive to thiamine deficiency, as cardiac muscle relies heavily on thiamine-dependent oxidative metabolism for its high ATP demands. Wet beriberi causes dilated cardiomyopathy, high-output heart failure, and tachycardia that reverse with thiamine repletion.

• vitamin B12Scientific

  Vitamin B12 is involved in homocysteine metabolism, and deficiency can raise circulating homocysteine levels, which are epidemiologically associated with increased cardiovascular disease (CVD) risk. However, despite B12 supplementation reliably lowering homocysteine, clinical trials and Cochrane reviews have consistently found no significant reduction in heart attack, cardiovascular mortality, or CVD events. The NIH ODS concludes that current evidence does not support vitamin B12 supplementation for reducing cardiovascular disease risk.

• vitamin B2Scientific

  Riboflavin is converted to its coenzyme forms (FAD/FMN) in cardiac tissue and small reserves are stored in the heart. FAD supports the mitochondrial electron transport chain in cardiac myocytes, essential for cardiac ATP production. The NIH ODS and National Academies DRI book both document the heart as a primary site of riboflavin metabolism and storage.

• vitamin B3 (niacin)Scientific

  Vitamin B3 (niacin) has an extensively studied, clinically documented relationship with cardiovascular health, primarily through its potent effects on lipid profiles: raising HDL-C by ~30–35%, lowering LDL-C and triglycerides. Early landmark trials (e.g., the Coronary Drug Project) demonstrated meaningful reductions in coronary events, but two large modern RCTs (AIM-HIGH and HPS2-THRIVE) found no added benefit when niacin was added to optimal statin therapy. A 2024 NIH-funded study further identified excess niacin metabolites (2PY, 4PY) as potentially pro-inflammatory and linked to increased cardiovascular risk, adding important complexity to the picture.

• vitamin B9 (folate)Scientific

  Folate (Vitamin B9) has well-documented biological relevance to cardiovascular health, primarily through its role in lowering plasma homocysteine, an established cardiovascular risk biomarker. Clinical trial evidence shows a modest but significant reduction in stroke risk with folic acid supplementation, while benefits for coronary heart disease specifically are less clear. Evidence is strongest in folate-deficient populations or those with elevated homocysteine, and weaker or absent in populations with adequate dietary folate intake.

• vitamin CScientific

  Vitamin C improves endothelial and vasomotor function of coronary arteries and supports collagen synthesis essential for vascular wall integrity. Observational data associate higher intake with reduced myocardial infarction risk, while RCT evidence for hard cardiac endpoints remains limited and of low quality.

• vitamin DScientific

  Substantial clinical and observational evidence links vitamin D status to cardiovascular health. Low serum 25(OH)D is consistently associated with increased risk of hypertension, coronary artery disease, heart failure, and cardiovascular mortality across large prospective cohort studies. However, major randomized controlled trials—including the landmark VITAL trial—have not demonstrated that supplementation reduces major cardiovascular events in the general population, leaving the causal direction debated. Mechanistic data show plausible biological pathways, and emerging evidence suggests benefit may be confined to those with frank deficiency or specific comorbidities.

• wasabiScientific

  In a rat metabolic syndrome model, wasabi supplementation attenuated acute inflammatory changes in the heart and reduced cardiac lipid deposition. 6-MSITC's endothelial Nrf2/HO-1 activation, antiplatelet activity, and suppression of inflammatory mediators collectively protect cardiac tissue. Anti-atherosclerotic properties address the most common pathology underlying heart disease.

• watermelonScientific

  Watermelon bioactives directly benefit cardiac function: lycopene reduces oxidative stress on myocardial tissue, and citrulline-derived NO reduces cardiac afterload by lowering blood pressure and arterial stiffness. RCTs in heart failure patients show improved flow-mediated dilation and reduced triglycerides with lycopene supplementation.

• wheatScientific

  Whole-grain wheat consumption is associated with reduced ischemic heart disease risk in prospective cohort studies. RCTs demonstrate blood pressure reduction and improvements in arterial function. Whole-grain wheat ferulic acid protects against LDL oxidation and platelet aggregation, processes central to atherosclerosis and coronary heart disease.

• wheat germScientific

  Wheat germ provides phytosterols, vitamin E, fiber, and omega-3 fatty acids that support heart muscle function and reduce cardiovascular risk factors. Animal studies show wheat germ supplementation reduces cardiac lipid oxidation susceptibility and may alleviate cardiac mitochondrial dysfunction in obesity. Vitamin E is particularly important for protecting cardiomyocyte membranes.

• yerba mateScientific

  Human clinical evidence shows yerba mate reduces LDL-cholesterol, increases HDL-C and its protective enzyme PON-1, reduces blood pressure, and is associated with lower cardiovascular disease incidence in large observational cohorts. Polyphenols and saponins are the primary active compounds.

• zeaxanthinScientific

  Zeaxanthin has been examined for cardiac protection through antioxidant and anti-inflammatory mechanisms. Observational data link low serum zeaxanthin with higher cardiovascular mortality in hypertensive adults. An animal RCT found zeaxanthin heneicosylate ameliorated age-related cardiac dysfunction via retinoid receptor activation, though human RCT evidence for direct cardiac benefit from supplementation remains limited.

• zincScientific

  Multiple clinical and epidemiological studies demonstrate a meaningful link between zinc status and cardiac health. Zinc deficiency is consistently associated with increased risk of coronary heart disease, heart failure, and adverse cardiovascular events. Its roles in anti-oxidative stress, anti-inflammatory signaling, and maintaining myocardial structure underpin these associations. Evidence is largely observational; RCT evidence shows benefit on cardiovascular risk factors (lipids, glucose) but direct interventional proof of reducing hard cardiac endpoints remains limited.

• amberTraditional

  In TCM, amber enters the Heart channel and is used for palpitations, arrhythmia, chest pain, angina, and conditions attributed to heart spirit disturbance or blood stasis obstructing heart vessels. Succinic acid's role in cardiomyocyte metabolism provides limited mechanistic support.

• asparagusTraditional

  Asparagus is listed as 'cardiac' in traditional herbal pharmacopoeias, indicating documented use as a heart tonic. Eastern European and Asian decoctions of asparagus were used for cardiovascular diseases including heart conditions. ACE-inhibitory, antihypertensive, and antioxidant properties provide mechanistic relevance, but no human RCT evidence for heart-specific outcomes exists.

• biota seedTraditional

  The Heart is biota seed's primary meridian and organ target in TCM. Classified as a Heart-nourishing, Shen-calming herb, it is used in the most important classical Heart-directed formulas for palpitations, insomnia, restlessness, and forgetfulness due to Heart Yin and Blood deficiency. This is one of the most well-documented traditional relationships in Chinese herbal medicine.

• fu lingTraditional

  In TCM, Fu Ling 'enters the Heart channel' and is used for palpitations, anxiety, and restlessness — manifestations attributed to Heart Qi or Blood deficiency. The Chinese Pharmacopoeia lists palpitations as a primary indication. Modern research has shown P. cocos sclerotium improves cardiac function via the AVP-V2R-AQP2 axis in heart failure models.

• jujubeTraditional

  Jujube has been prescribed as a 'heart tonic' in TCM, Korean, and Islamic Prophetic medicine for centuries. Modern RCT evidence shows improvement in cardiovascular risk factors (lipids, glucose) but no direct cardiac function or structural outcomes have been tested in humans. Prophetic and Islamic classical sources specifically cite jujube's benefits for cardiac temperament.

• lilyTraditional

  Lily bulb is officially indicated in the Chinese Pharmacopoeia for palpitations and is described as clearing Heart fire and calming the Heart spirit. These are well-documented TCM indications for Heart Yin deficiency patterns. Na⁺/K⁺-ATPase inhibitory activity of steroidal saponins is a noted pharmacological finding of potential cardiac relevance. No human cardiac trials exist.

• passionflowerTraditional

  Passionflower has a documented traditional role as a cardiac nervine, used for palpitations, tachycardia, and irregular heart action arising from nervous excitement or anxiety. Eclectic physicians specifically listed 'cardiac palpitation from excitement or shock' as an indication. At high doses, pharmacological data indicate potential for slowed or irregular heart rhythms, suggesting direct cardiac electrophysiological activity.

• polygalaTraditional

  The heart is a primary TCM organ target of Yuan Zhi, which is assigned to the Heart meridian in the Chinese Pharmacopoeia and used in formulas for palpitations, heart-kidney disharmony, and emotional disorders attributed to heart qi disturbance. Preclinical antiarrhythmic and cardioprotective data support this traditional classification.

• polygala rootTraditional

  The Heart is formally listed as a target meridian of Polygala root in the Chinese Pharmacopoeia. TCM uses include palpitations, cardiac anxiety, and emotional instability related to heart-kidney imbalance. The root is classified as 'cardiotonic' in traditional sources.

• rehmanniaTraditional

  In TCM, Rehmannia enters the heart channel and is prescribed for palpitations, insomnia, and blood deficiency affecting cardiac function. It is a core ingredient of Tian Wang Bu Xin Dan, the classical formula for heart and kidney yin deficiency. The Restorative Medicine monograph lists coronary heart disease (postmenopausal) as a documented indication.

• skullcapTraditional

  S. lateriflora was prescribed by Eclectic physicians for 'heart disorders of the nervous type with intermittent pulse' and palpitations. S. baicalensis demonstrates cardioprotective effects (baicalin) against myocardial injury, arrhythmia, and drug-induced cardiotoxicity in preclinical models. Clinical application of Huang Qin for cardiac conditions in China is documented.

• solomon's sealTraditional

  Solomon's seal is classified as a mild heart tonic in TCM and by Western herbalists, with documented use for coronary heart disease in Chinese medicine. The rhizome contains a cardio-tonic glycoside. Animal studies demonstrate lipid-lowering and cardioprotective effects of Polygonatum extracts.

• star of bethlehemTraditional

  The heart is the pharmacologically best-characterised target of Star of Bethlehem's bioactive constituents. The bulbs contain cardiac glycosides (convallatoxin, convalloside, rhodexin A) that inhibit sodium-potassium ATPase, slowing heart rate and increasing contractility analogously to digoxin. Traditional use for congestive heart failure is documented and was the subject of early human clinical investigations in the 1950s–1960s, though no modern trials exist.

• swertiaTraditional

  Swertia chirayita is traditionally described as a cardiostimulant and heart protectant in Ayurvedic and folk medicine. Pharmacological reviews confirm cardiostimulant among the documented properties. Plant formulations containing S. chirayita are noted to protect the heart and regulate blood pressure in research overviews.

• tribulusTraditional

  Tribulus has traditional use in TCM and Ayurveda specifically for cardiac conditions including angina pectoris and coronary circulation. Animal and in vitro studies support cardioprotective mechanisms via NO release, antioxidant protection of ischemic cells, and ACE inhibition. No dedicated cardiac RCT exists.

• valerian rootTraditional

  Traditional herbal medicine has long applied valerian root to heart palpitations, anxiety-related tachycardia, and as an adjunct in mild hypertension. Preclinical data document coronary vasorelaxation, protective effects against vasopressin-induced coronary spasm, and traditional antiarrhythmic use documented in ethnopharmacological records. Direct human RCT evidence for cardiac endpoints is absent.